What is the efficacy of Sotoraxibu (AMG510)?

In aPhase II clinical trial, sotoraxib (AMG510) showed good tolerability and efficacy in the treatment of NSCLC patients with KRAS G12C mutations. The results of the study showed that sotoracib caused tumor shrinkage in approximately 36% of patients, and approximately 4% of patients experienced complete tumor shrinkage. This is a positive result, especially considering that the KRAS G12C mutation is relatively common in NSCLC and difficult to treat. In the Phase I/II CodeBreaK 100 trial, sotoraxib was studied in the treatment of KRAS Efficacy in G12C mutation-positive non-small cell lung cancer, sotoraxib 180-960mg once daily has potential efficacy (the primary endpoint is safety), in which 19 patients (32.2%) with non-small cell lung cancer achieved confirmed partial response (PR) .